Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...
Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more about RXRX stock here.
RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...
Recursion Pharmaceuticals, Inc. upgraded to Buy on promising REC-4881 data, strong partnerships, and AI-driven drug discovery ...
The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback